Italian dairy company Parmalat, owned by French peer Lactalis, is to launch an e-commerce offering after what its describes as the “unprecedented growth” of online shopping during the Covid-19 period.
It suggested it has opened a “new dialogue with customers” that allows them to buy “safely and fast” milk, creams, juices, dessert and also meat and cheese.
The online shop, which the firm said is a response to the “changed behaviour of consumers who are increasingly choosing online purchases,” is now a permanent feature of the company’s website.
Giovanni Pomella, general director for Parmalat’s Italian business unit, said: “This project was born into a journey of digital transformation which will create new business opportunities through a fast-growing channel.
“Considering the change of habits, it is important to open a dialogue with consumers. We have the ambition to provide not only products, but also a buying experience, which will evolve to be consistent with the needs of Italian families.”
The portal was developed in partnership with marketing and shipping business Deliverti.
Parmalat pointed out that, prior to the lockdown, Italy has one of the lowest take-up rates of e-commerce in Europe.
COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence. GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into:
COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments